PolyPid
$ 4.83
2.33%
04 Jun - close price
- Market Cap 93,378,000 USD
- Current Price $ 4.83
- High / Low $ 4.85 / 4.66
- Stock P/E N/A
- Book Value 0.60
- EPS -1.74
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.15 %
- ROE -7.59 %
- 52 Week High 5.21
- 52 Week Low 2.77
About
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Analyst Target Price
$12.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-02-11 | 2025-11-12 | 2025-08-13 | 2025-05-14 | 2025-02-12 | 2024-11-13 | 2024-08-14 | 2024-05-08 | 2024-02-14 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.35 | -0.41 | -0.37 | -0.78 | -0.7 | -1.07 | -1.22 | -1.25 | -1.37 | -3.84 | -3.4 | -10.8 |
| Estimated EPS | -0.43 | -0.33 | -0.52 | -0.55 | -0.82 | -0.88 | -1 | -1.3 | -1.41 | -4.29 | -4.43 | -13.32 |
| Surprise | 0.08 | -0.08 | 0.15 | -0.23 | 0.12 | -0.19 | -0.22 | 0.05 | 0.04 | 0.45 | 1.03 | 2.52 |
| Surprise Percentage | 18.6047% | -24.2424% | 28.8462% | -41.8182% | 14.6341% | -21.5909% | -22% | 3.8462% | 2.8369% | 10.4895% | 23.2506% | 18.9189% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PYPD
2026-06-01 17:09:10
PolyPid Ltd. has finished its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, a drug designed to improve surgical outcomes by providing controlled, continuous delivery of medicines. The company, a clinical-stage biopharmaceutical firm based in Israel, concentrates on developing innovative, locally administered therapies. This submission marks a significant milestone in PolyPid's efforts to bring D-PLEX100 to market.
2026-06-01 17:09:10
PolyPid Ltd. has completed its New Drug Application (NDA) submission to the FDA for D-PLEX₁₀₀, a drug designed to prevent surgical site infections during colorectal surgery. The submission is supported by positive Phase 3 trial results showing a 60% relative risk reduction in infections. PolyPid anticipates a potential FDA decision in the first quarter of 2027 and is preparing for the drug's potential approval and launch.
2026-06-01 16:11:14
PolyPid has completed its rolling New Drug Application (NDA) submission to the FDA for D-PLEX100, a drug-device combination product for extended-release local antibacterial therapy. The submission seeks approval for D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal surgery. This marks a significant step towards bringing D-PLEX100 to market to address a critical unmet medical need.
2026-06-01 12:09:42
PolyPid (Nasdaq: PYPD) has successfully submitted its New Drug Application (NDA) to the U.S. FDA for D-PLEX100, its lead drug candidate to prevent surgical site infections in patients undergoing colorectal surgery. The NDA is supported by positive Phase 3 SHIELD II trial results showing a 60% relative risk reduction in infections. The company anticipates a potential FDA decision in the first quarter of 2027 and is actively pursuing commercial partnership discussions.
2026-06-01 12:09:42
PolyPid Ltd. has completed its New Drug Application (NDA) submission to the FDA for D-PLEX 100, a drug candidate aimed at preventing surgical site infections in colorectal surgery patients. The company anticipates an FDA decision in the first quarter of 2027. D-PLEX 100 has received Breakthrough Therapy, Fast Track, and QIDP designations and demonstrated a 60% relative risk reduction in SSIs during its Phase 3 SHIELD II trial.
2026-06-01 01:09:50
PolyPid Ltd (PYPD) stock on Nasdaq is experiencing quiet trading as investors await significant catalysts like trial readouts, regulatory decisions, or financing events. The clinical-stage biopharmaceutical company, based in Israel, focuses on locally delivered therapies for infection prevention and oncology care. Its shares, a small-cap biotech, are influenced by broader market sentiment and expectations of future milestones rather than recent company-specific news.
